All News
Sinusitis Linked to 40% Heightened Risk of Rheumatic Disease
d
EurekAlert!
The common inflammatory condition sinusitis is linked to a 40% heightened risk of a subsequent diagnosis of rheumatic disease, particularly in the 5 to 10 years preceding the start of symptoms, finds research published in the open access journal RMD Open.
Read Article
EGPA: Benralizumab or Mepolizumab
A multicenter, double-blind, phase 3, randomized, active-controlled trial has shown that Benralizumab (BEN) was noninferior to mepolizumab (MEP) for the induction of remission of patients with relapsing or refractory Eosinophilic granulomatosis with polyangiitis (EGPA).
Read Article
Behçet’s Syndrome
A comprehensive overview of Behcet's syndrome appeared in last week's NEJM, reviewing the numerous advances in the immunogenetics, syndrome recognition, and targeted therapeutic approaches.
Read Article
PAPA (pyogenic arthritis, pyoderma gangrenosum & acne) syndrome is a hereditary autoinflammatory Dz caused by dominant mutation in PSTPIP1 (triggers IFN-γ-mediated pyrin induction & IL-18 release; can be Tx by JAK inhibition) https://t.co/fy0MnwDA5U https://t.co/l8n2EwgV0t
Dr. John Cush RheumNow ( View Tweet)
FDA approves 10th adalimumab biosimilar - called Simlandi (adalimumab-ryvk), from Alvotech and Teva. Unique in that it's the 1st high-concentration, citrate-free & interchangeable ADA biosimilar.https://t.co/V6zbCnpfvn https://t.co/igLddGMcoM
Dr. John Cush RheumNow ( View Tweet)
Norway study 1558 chart-reviewed SLE cases; 797 were new-onset SLE from 1999 to 2017. During this period the annual SLE incidence rates fell; mostly pronounced in women 50-59 yrs (fell 3.4 to 1.1 per 100K) - paralleled by 74% reduction menopausal HRT https://t.co/zYkXAnEcOI https://t.co/oaz9t65zZy
Dr. John Cush RheumNow ( View Tweet)
Australian study shows self-reported difficulties w/ ambulation (limited<=1 km) had a higher risk of hip and spinal fractures (32% to 219% more)/ Included 239 000 adults >45 yrs https://t.co/IWvKmPc2t8 https://t.co/CDYDzhMUoa
Dr. John Cush RheumNow ( View Tweet)
When Meningitis Strikes Twice
Amanda Moyer, MD, presents her poster at RWCS 2024.
https://t.co/er2E2XnrZZ https://t.co/vwDopOLPRH
Dr. John Cush RheumNow ( View Tweet)
With New Medications Come New Myopathies
Alexia Hwang, MD, presents her poster at RWCS 2024.
https://t.co/BjYxKk2QlW https://t.co/vDA0dllMQz
Dr. John Cush RheumNow ( View Tweet)
Immunosuppression Increasing
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks on https://t.co/V10S4oVFsv; but begins with a discussion of what constitutes "immunosuppression" and how it applies to our patients.
https://t.co/KvZIiKowox https://t.co/cbBYydVQbB
Dr. John Cush RheumNow ( View Tweet)
Single center study of 163 pts (mostly RA) Rx w/ tocilizumab found 41 hospitalized & 49% for serious infx. SIE were more common w/ eosinopenia (EC < 0.05 g/L; avg (0.06 vs 0.20 g/L) & low ratio EC/NC ratio (× 1000 < 11.8) (median (6.54 vs 48.50). https://t.co/88sbHBIhXt https://t.co/6wUeqSbVxx
Dr. John Cush RheumNow ( View Tweet)
No clear link between weather & MSK symptoms
There is a belief that changes in weather conditions, such as impending rain or temperature, can trigger or worsen muscle and joint pain but Australian researchers have found no clear pattern between the two.
https://t.co/V3rfCTWRBQ https://t.co/eFdZH4LoNA
Dr. John Cush RheumNow ( View Tweet)
CD19 CAR T-Cell Therapy in Autoimmune Disease
The NEJM has published the results of CD19 B cell depletion (by CAR-T cell therapy) in autoimmune disease patients, demonstrating it to be feasible, safe, and efficacious.
https://t.co/ym3pAsI5Sf https://t.co/AnfKOISscV
Dr. John Cush RheumNow ( View Tweet)
RA BIOBADASER registry study of 1128 patients going on ts/bDMARD found 107 (9.3%) w/ multimorbidity (Charlson Comorbidity index ≥ 3). Multimorbid RA were older, more SJC & signif higher DAS28; ts/bDMARD retention rate equal groups https://t.co/am4Uoccla9 https://t.co/P7Ae2Jal2e
Dr. John Cush RheumNow ( View Tweet)
Feb 2024 EMA meeting approved biosimilar ustekinumab (Pyzchiva) for adult/pediatric psoriasis; psoriatic arthritis; UC/Crohn's. & also approved generic Apremilast Accordfor the treatment of psoriatic arthritis, psoriasis, and Behçet disease https://t.co/Cu9f4qQjgP https://t.co/qmH3ZkfReN
Dr. John Cush RheumNow ( View Tweet)
Congratulations to Drs. David Felson Tuhina Neogi of Boston University in being awarded a U19 5 yr grant to fund Novel Insights into Osteoarthritis, Pain and Function: The Multicenter Osteoarthritis (MOST) Study. https://t.co/fGU9Zk2ECs https://t.co/dtT0hu7aA1
Dr. John Cush RheumNow ( View Tweet)
MMPs play pathogenic role in RA-ILD. Multicenter VA study of 2,312 RA pts, 96 had prevalent ILD & Incident ILD developed in 130 (IR 7.5/1,000PY). High MMP-7 increased ILD (adj OR 3.78) & incident ILD (adj HR 2.33). Higher MMP-9 did same https://t.co/3i49TsAQbt https://t.co/RA6Fu2jPeE
Dr. John Cush RheumNow ( View Tweet)
Eating for RA
The majority of practicing rheums at RheumNow Live were unaware of the new ACR guidelines issued in 2022 regarding dietary and lifestyle recommendations for patients with RA. Dr. Monica Guma reviewed these guidelines during her lecture.
https://t.co/9herN2musx https://t.co/P1xJn2lDrg
Dr. John Cush RheumNow ( View Tweet)
Serial plasma samples assayed for 92 inflammation-related proteins, during and after gout attacks. 21 were differentially expressed. Gout flares assoc w/ increased IL-6, CSF-1, VEGF-A & tumour necrosis factor superfamily 14 (TNFSF14 was highest) https://t.co/2p8vTFcmvD https://t.co/5z1gYdsKJO
Dr. John Cush RheumNow ( View Tweet)
Week 52 outcomes of 180 lupus nephritis pts (IV, VI, III) from AMP academic centers (rx w/ standard of care) showed 22% complete resp, 22% partial resp, 42% non-responder& 14% undetermined. 8/180 (4.4%) had CR sustained Wk 12 to 52; 10% PR. An unmet need! https://t.co/MJklf0Xhih https://t.co/w6a1fLKmoF
Dr. John Cush RheumNow ( View Tweet)
